Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial

OBJECTIVES: Varenicline was approved by the FDA in 2006. In 2009, based largely on case reports, the FDA issued a warning of possible adverse neuropsychiatric effects including depression and suicidal thoughts and behavior for varenicline and bupropion. Prospective trials of varenicline have not rep...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Pachas, Gladys N., Cather, Corinne, Pratt, Sarah A., Hoeppner, Bettina, Nino, Johanna, Carlini, Sara V., Achtyes, Eric D., Lando, Harry, Mueser, Kim T., Rigotti, Nancy A., Goff, Donald C., Evins, A. Eden
פורמט: Artigo
שפה:Inglês
יצא לאור: 2012
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3414422/
https://ncbi.nlm.nih.gov/pubmed/22888309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15504263.2012.663675
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים